Smart pens enhance blood glucose compliance rates, and real-world studies confirm their clinical value

At the 2024 American Diabetes Association (ADA) Annual Meeting, two real-world studies presented positive data for NovoPen 6 and NovoPen Echo Plus. The studies covered over 20,000 patients in Austria and 21 other countries, and the results showed that:
After using the smart insulin pen, the time spent within the target glucose range (TIR) of patients has significantly increased, especially among those with a baseline TIR of less than 40%, where the increase is the greatest;
The rate of missed insulin injections during meals decreases, and adherence improves with increased frequency of use and age.
This technology connects to a smartphone app via NFC, automatically recording injection time and dosage, assisting doctors in remotely adjusting treatment plans.